Colon cancer is the second leading cause of cancer deaths in the U.S., and a new study shows it may also raise the risk of ...

A new smart liner called Roliner lets amputees adjust prosthetic fit in real time via smartphone, easing pain and improving ...

ATTR-CM is a disease in which harmful proteins build up in the heart, making it harder to pump blood, according to the ...

Alnylam Pharmaceuticals (NASDAQ:ALNY – Get Free Report) was upgraded by JPMorgan Chase & Co. from a “neutral” rating to an ...

Fintel reports that on March 24, 2025, JP Morgan upgraded their outlook for Alnylam Pharmaceuticals (NasdaqGS:ALNY) from ...

Sarepta Therapeutics (SRPT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

The Sanofi drug, known as fitusiran and now Qfitlia, was approved on Friday for a broad group of people with the rare ...

CM, expanding its market reach. JP Morgan upgrades the stock, projecting strong sales and a multi-billion opportunity.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY – Get Free Report) has earned a consensus rating of “Moderate Buy” from the twenty ...

Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in ...

Over the last three years, the FDA has approved six new hemophilia drugs, including three gene therapies. | Over the last ...